Dear Dr. Renukaprasad A R,  Do you know that Ramiven ® is approved in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive early breast cancer (EBC) patients at high risk of recurrence? Several clinical trials suggested that up to 30% of HR+ HER2- node-positive EBC patients with high-risk clinical characteristics may experience distant recurrence. Therefore, superior treatment options are needed to prevent early recurrence and the development of metastases. Abemaciclib is the first CDK4/6 inhibitor to establish a significant improvement in HR+ HER2- node-positive EBC patients at high risk of early recurrence. Be a part of an exclusive session where renowned international and national oncology experts discuss their perspectives on the high unmet needs in EBC and the benefits that Ramiven ® for high-risk EBC patients in India. Have you missed the Ramiven ® EBC launch program?
Not an issue! We have saved the recording just for YOU!
We hope the discussion will give you insights into the recent advancements in the field of breast cancer and will help you in your practice.
| .jpg)
No comments:
Post a Comment